![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis
|
|
|
Reported by jules Levin
CROI 2016 Feb 22-24 Boston
Jay A. Grobler, Ming-Tain Lai, Stephanie E. Barrett, Marian Gindy, Kerry Fillgrove, Wendy Ankrom, Sandra Wood, Evan Friedman, Marian Iwamoto, Daria J. Hazuda on behalf of the MK-8591 Early Development Team (West Point, PA)
Merck & Co., Inc. Kenilworth, NJ, USA
WEBCAST link: http://www.croiwebcasts.org/console/player/29624?mediaType=audio&
![APASL1](../images/022416/022416-9/APASL1.gif)
![APASL2](../images/022416/022416-9/APASL2.gif)
![APASL3](../images/022416/022416-9/APASL3.gif)
![APASL4](../images/022416/022416-9/APASL4.gif)
![APASL5](../images/022416/022416-9/APASL5.gif)
![APASL6](../images/022416/022416-9/APASL6.gif)
![APASL7](../images/022416/022416-9/APASL7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|